RASP (Actavia Life Sciences) Effective Interest Rate on Debt %: 37.74% (As of Mar. 2024)


What is Actavia Life Sciences Effective Interest Rate on Debt %?

Actavia Life Sciences RASP -87.50% Effective Interest Rate on Debt % is 37.74% as of Mar. 2024.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Actavia Life Sciences's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.10 Mil. Actavia Life Sciences's average total debt for the quarter that ended in Mar. 2024 was $0.27 Mil. Therefore, Actavia Life Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 37.74%.

Actavia Life Sciences  (OTCPK:RASP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Actavia Life Sciences Effective Interest Rate on Debt % Related Terms

Actavia Life Sciences Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Effective Interest Rate on Debt % Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.93 10.42 85.64 208.42 98.84

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 306.04 9.17 18.74 42.11 37.74

RASP vs BWV, FNCH, CWBR: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Actavia Life Sciences's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Effective Interest Rate on Debt % falls into.


Actavia Life Sciences Effective Interest Rate on Debt % Calculation

Actavia Life Sciences's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Sep. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Sep. 2022 )+Total Debt  (A: Sep. 2023 ))/ count )
=-1  *  -0.213/( (0.22+0.211)/ 2 )
=-1  *  -0.213/0.2155
=98.84 %

where

Total Debt  (A: Sep. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.092 + 0.128
=0.22

Total Debt  (A: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0.211
=0.211

Actavia Life Sciences's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -0.1/( (0.226+0.304)/ 2 )
=-1  *  -0.1/0.265
=37.74 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0.226
=0.226

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0.304
=0.304

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 37.74% mean?
Actavia Life Sciences (RASP) has a Effective Interest Rate on Debt % of 37.74% as of Mar. 2024. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Effective Interest Rate on Debt % too high?
Actavia Life Sciences' current Effective Interest Rate on Debt % is 37.74%.
How does Actavia Life Sciences' Effective Interest Rate on Debt % compare to BWV and FNCH?
Actavia Life Sciences' Effective Interest Rate on Debt % of 37.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Effective Interest Rate on Debt % is 37.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Effective Interest Rate on Debt % of 37.74%. The current Effective Interest Rate on Debt % is 37.74%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Effective Interest Rate on Debt % is 37.74% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.